BRAIN Biotech receives €11.51m Royalty Pharma milestone payment for deucrictibant

BRAIN Biotech has received an €11.51 million milestone payment from Royalty Pharma linked to development progress for deucrictibant.

The payment was triggered under BRAIN Biotech's existing royalty monetisation arrangement as development of the investigational therapy reached a contractual milestone.

The receipt strengthens BRAIN Biotech's near-term financial position while demonstrating continued value generation from its legacy participation in deucrictibant.

Field	Content
Alert Type	Milestone payment
Company	BRAIN Biotech
Counterparty	Royalty Pharma
Drug / Asset	Deucrictibant
Payment	€11.51 million
Transaction Context	Existing royalty monetisation agreement
What Happened	BRAIN Biotech received an €11.51 million development milestone payment from Royalty Pharma.
Why It Matters	The payment provides a material cash inflow and demonstrates continued economic value from BRAIN Biotech's interest in deucrictibant.
Supporting Context	The payment arises from an existing Royalty Pharma arrangement rather than a newly signed licensing transaction.
Key Takeaway	Progress in deucrictibant development has triggered a significant milestone payment to BRAIN Biotech.
What to Watch	Further clinical and regulatory milestones for deucrictibant and any additional payments arising under the royalty arrangement.
Primary Source	BRAIN Biotech
Relevant Date	September 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com